Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atai Beckley N.V. (ATAI)

Tipranks - Tipranks - Sat Apr 18, 7:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Atai Beckley N.V. (ATAI) with bullish sentiments.

Claim 30% Off TipRanks

Eli Lilly & Co (LLY)

In a report released yesterday, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly & Co, with a price target of $1163.00. The company’s shares closed last Thursday at $903.99.

According to TipRanks.com, Fernandez is a 5-star analyst with an average return of 27.0% and a 62.0% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Sagimet Biosciences, Inc. Class A, and Mineralys Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1247.71 average price target, implying a 36.9% upside from current levels. In a report issued on April 1, TipRanks – xAI also upgraded the stock to Buy with a $984.00 price target.

See today’s best-performing stocks on TipRanks >>

Atai Beckley N.V. (ATAI)

In a report released yesterday, Eddie Hickman from Guggenheim reiterated a Buy rating on Atai Beckley N.V., with a price target of $16.00. The company’s shares closed last Thursday at $4.09.

According to TipRanks.com, Hickman is a 4-star analyst with an average return of 20.4% and a 60.0% success rate. Hickman covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, ProMIS Neurosciences, and Zevra Therapeutics. ;'>

Currently, the analyst consensus on Atai Beckley N.V. is a Strong Buy with an average price target of $14.60, a 265.0% upside from current levels. In a report issued on April 5, Oppenheimer also assigned a Buy rating to the stock with a $16.00 price target.

Read More on LLY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).